Home/Tag: PDGFRA

Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors

By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought [...]

By |2019-10-31T12:01:09-04:00October 16th, 2015|News, Research|

Being Your Own Warrior: Karen Darnell’s Personal Battle

Karen Darnell appreciates the value of life jackets. In her GIST journey, she recognizes the importance of having one constructed from the fabric of family support, GIST experts, email communities and the Life Raft [...]

By |2018-11-06T12:58:26-05:00June 16th, 2015|Member Stories, News|

Sosipatros Boikos takes helm at NIH Clinic

Dr. Sosipatros Boikos, a graduate of University of Crete in Greece, very early and while he was a first year medical student, developed an interest in cancer genetics. After graduating from medical school, he came to the National Institutes of Health as a Visiting Research Fellow to work on the genetics of Wildtype gastrointestinal stromal tumors—those GIST tumors without a KIT or PDGFRA mutation—under the supervision of Dr. Constantine Stratakis, the researcher who identified Carney-Stratakis Syndrome.

By |2019-09-20T12:16:19-04:00August 9th, 2013|Clinical Trials, Events, News, Pediatric GIST|

Understanding How GISTs Develop Enables Discovery of New Therapies

By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team   Researchers talk plainly about microGISTs, how this cancer develops and what all [...]

By |2019-09-20T13:22:48-04:00January 23rd, 2013|Clinical Trials, Diagnosis, GIST Education, Mutations, News, Research|

The challenge of imatinib resistance in GIST

By Jonathan Fletcher, M.D. & Sebastian Buaer, M.D. Within the past decade, GISTs have emerged from being poorly defined, treatment-resistant tumors to a well recognized, well understood, and treatable tumor entity. Rapid advances in the understanding [...]

By |2019-12-30T09:53:24-05:00December 1st, 2008|News|

Looking for Kinase Mutations in GISTs

This is the second of a two-part series on KIT and PDGFRA mutations in GISTs, written collaboratively by Drs. Michael Heinrich and Christopher Corless, LRG research team members. Please refer to the May issue of our newsletter for the first part titled, “KIT & PDGFRA mutations in GIST: A to Z” by Dr. Heinrich.

By |2018-05-29T13:29:32-04:00May 11th, 2007|Mutational Testing, Mutations|

Mutational testing predicts GIST treatment response

The ability of mutational analysis to predict the response of GIST tumors to Gleevec has been known since Dr. Charles Blanke’s GIST presentation at the plenary session of the 2001 American Society of Clinical Oncology [...]

By |2016-04-01T14:03:19-04:00June 15th, 2006|Mutational Testing, News, Survival Strategies|
Go to Top